Cardio-ankle vascular index (CAVI) differentiates pharmacological properties of vasodilators nicardipine and nitroglycerin in anesthetized rabbits  by Chiba, Tatsuo et al.
ble at ScienceDirect
Journal of Pharmacological Sciences 128 (2015) 185e192Contents lists availaHOSTED BY
Journal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphsFull paperCardio-ankle vascular index (CAVI) differentiates pharmacological
properties of vasodilators nicardipine and nitroglycerin in
anesthetized rabbits
Tatsuo Chiba a, b, Mari Yamanaka a, Sachie Takagi a, Kazuhiro Shimizu c, Mao Takahashi c,
Kohji Shirai d, e, Akira Takahara a, *
a Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Chiba 274-8510, Japan
b Department of Pharmacy, Toho University Ohashi Medical Center, Meguro-ku, Tokyo 153-8515, Japan
c Cardiovascular Center, Toho University Sakura Medical Center, Sakura, Chiba 285-8741, Japan
d Department of Vascular Function, Toho University Sakura Medical Center, Chiba 285-8741, Japan
e Mihama Hospital, Chiba 261-0013, Japana r t i c l e i n f o
Article history:
Received 2 April 2015
Received in revised form
29 June 2015
Accepted 3 July 2015
Available online 14 July 2015
Keywords:
Nitroglycerin
Nicardipine
Phenylephrine
Doxazosin
Cardio-ankle vascular index (CAVI)* Corresponding author. Department of Pharmacolo
of Pharmaceutical Sciences, Toho University, 2-2-1 M
8510, Japan. Tel./fax: þ81 474 72 3225.
E-mail address: akirat@phar.toho-u.ac.jp (A. Takah
Peer review under responsibility of Japanese Pha
http://dx.doi.org/10.1016/j.jphs.2015.07.002
1347-8613/© 2015 The Authors. Production and hostin
license (http://creativecommons.org/licenses/by-nc-na b s t r a c t
Cardio-ankle vascular index (CAVI) has been developed for measurement of vascular stiffness from the
aorta to tibial artery, which is clinically utilized for assessing the progress of arteriosclerosis. In this study,
we established measuring system of the CAVI in rabbits, and assessed whether the index could reﬂect
different pharmacological actions of nitroglycerin and nicardipine on the systemic vasculature. Rabbits
were anesthetized with halothane, and the CAVI was calculated from the well-established basic equa-
tions with variables obtained from brachial and tibial blood pressure and phonocardiogram. Nicardipine
(1, 3 and 10 mg/kg, i.v.) decreased the blood pressure, femoral vascular resistance, and heart-ankle pulse
wave velocity (haPWV). Meanwhile, no signiﬁcant change was detected in the CAVI at the low or middle
dose, which reﬂects the deﬁning feature of the CAVI that is independent of blood pressure. The index
increased at the high dose. Nitroglycerin (2, 4 and 8 mg/kg, i.v.) decreased the blood pressure, femoral
vascular resistance, and haPWV. Meanwhile, the CAVI was decreased during the nitroglycerin infusion,
which may reﬂect its well-known pharmacological action dilating conduit arteries. These results suggest
that the CAVI differentiates the properties of these vasodilators in vivo.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Systemic circulation is mainly regulated by cardiac function,
which also propped by vascular stiffness known as the Windkessel
function (1). However, such vascular function had been difﬁcult to
be measured quantitatively. Recently, cardio-ankle vascular index
(CAVI) was developed, which reﬂects the arterial stiffness of the
arterial tree from the origin of the aorta to the tibial artery (2). The
equation of the CAVI is determined from combination of the theory
of stiffness parameter b, which expresses the changes of inner
pressure requiring some extension of the caliber of the arterial wallgy and Therapeutics, Faculty
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d/4.0/).(3), together with the equation of Bramwell-Hill (4). One of the
features of the CAVI is independency from the blood pressure at
measuring time (2). The CAVI has been clinically utilized for as-
sessments of the arterial stiffness to estimate progress of arterio-
sclerosis (2, 5), which is correlated well with other atherosclerotic
parameters, such as age, severity of coronary artery disease and
intima-media thickness of common carotid artery (6e11). Whereas
it is assumed that the stiffness of the artery measured by CAVI is
composed of organic stiffness (6e11) and functional stiffness
(12e14) based on clinical observations, the concept is needed to be
further strengthened by other procedures such as pharmacological
approaches.
Vasodilators are clinically used in accordance with each phar-
macological property. Ca2þ channel blockers, such as nifedipine,
nicardipine and amlodipine, dilate arterioles leading to reduction of
peripheral vascular resistance, which is used for the treatment of
hypertension (15, 16). On the other hand, a representative organicnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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and dilates all segments of the vascular system from large
conductance arteries to large veins, which is used for the treatment
of various cardiovascular diseases including angina and heart fail-
ure to reduce ventricular preload and afterload (17). Earlier studies
have demonstrated that such different pharmacological actions on
the vascular tree between Ca2þ channel blockers and organic ni-
trate have been investigated by measuring regional coronary
arterial resistance in the open-chest dog or the isolated blood-
perfused heart preparation (18e20). In those studies, it is shown
that nitroglycerin produces a preferential dilation of the large
conductance artery, while nifedipine dilates only of the small
resistive artery, which gives us fundamental information for opti-
mization of treatment of cardiovascular diseases. Whereas micro-
vascular diseases in the brain and kidney have been suggested to be
associated with arterial stiffening due to exposure of abnormally
high pulsatile stress in the microvessels (21), useful indexes of
arterial stiffness reﬂecting vascular functions of larger conductance
arteries are at present unavailable using less invasive methods. In
this study, we established the measuring system of CAVI in rabbits
to assess its usefulness as an index for stiffness of large conduit
arteries by comparing effects of nitroglycerin and nicardipine on
the CAVI. We further investigated a role of a1-adrenoceptors
pharmacologically to better understand the sympathetic regulation
of arterial stiffness.
2. Materials and methods
All experiments were approved by the Ethics Committee of Toho
University and performed in accordance with the Guiding Princi-
ples for the Care and Use of Laboratory Animals approved by The
Japanese Pharmacological Society.
2.1. Measurements of hemodynamics, CAVI and haPWV
Male or female New Zealand White rabbits weighing 3e4 kg
were initially anesthetized with ketamine (35 mg/kg, i.m.) and
xylazine (5 mg/kg, i.m.). After intubation of the tracheal cannula,
0.5% halothane vaporized with 100% oxygen was inhaled with a
ventilator (SN-480-7, Shinano, Tokyo). The tidal volume and res-
piratory rate were set at 6 mL/kg and 40 strokes/min, respectively,
and body temperaturewasmaintained at 37 C using a heating pad.
The schema of this apparatus measuring the CAVI is illustrated in
Fig. 1. The right and left ear veins were cannulated for drug
administration. The surface lead II electrocardiogramwas obtained
from the limb electrodes. Phonocardiogram was recorded using a
microphone placed on the thorax. A heparinized catheter was
inserted through the right brachial and tibial artery for continuousFig. 1. Schema of the measurement system of CAVI in the anesthetized rabbit. BP,
blood pressure; ECG, electrocardiogram; PCG, phonocardiogram; L, a length from
aortic valve to ankle.measurements of the blood pressure using a transducer. The
femoral arterial blood ﬂowwasmeasured using an ultrasonic blood
ﬂowmeter (TS420, Transonic Systems Inc., Ithaca, New York, USA).
All signals were recorded with PowerLab system (AD Instruments,
Bella Vista, New South Wales, Australia).
The femoral vascular resistance was calculated using the basic
equation: mean blood pressure/femoral arterial blood ﬂow. For
measurements of the heart-ankle pulsewave velocity (haPWV) and
CAVI, the signals of electrocardiogram, phonocardiogram and blood
pressure were fed to VaSera VS-1500 (Fukuda Denshi Co. LTD,
Tokyo) to be automatically calculated from the following well-
established basic equations (2). CAVI and haPWV are indicated by
the following formulae:
CAVI ¼ a (2r/DP)  ln(Ps/Pd)  haPWV2 þ b
where Ps is systolic blood pressure [Pa], Pd is diastolic blood
pressure [Pa], haPWV is heart-ankle pulsewave velocity [m/s], DP is
PsePd [Pa], r is blood density [kg/m3], and a and b indicate a
constant (a ¼ 1, b ¼ 0 for this study). The index is expressed as
International System of Units.
haPWV ¼ L/T (T ¼ tba þ tb)
where L is a length from aortic valve to ankle [m], T is time taken for
the pulse wave to propagate from the aortic valve to the ankle [s],
tba is time between the rise of brachial pulse wave and the rise of
ankle pulse wave [s], tb is time between aortic valve's closing sound
and notch of brachial pulse wave [s]. The time tb is estimated to be
equal to the time t'b showing time between aortic valve's opening
sound and the rise of brachial pulse wave. Since we used a unit of
mmHg for measurements of the blood pressure in this study, CAVI
can also be calculated as follows:
CAVI ¼ (2r [g/cm3]/DP [mmHg])  ln(Ps [mmHg]/Pd
[mmHg])  haPWV2 [m/s]  7.5
where 7.5 is a coefﬁcient converting mmHg to pascal for the blood
pressure and g/cm3 to kg/m3 for the blood density.
2.2. Experimental protocol
After the assessment of the basal condition, nicardipine at 1 mg/
kg was intravenously administrated over 10 min (0.2 mL/kg per
min) and each cardiovascular parameter was sequentially
measured until 30 min after the start of drug infusion (n¼ 6). Then,
effects of nicardipine at 3 mg/kg or 10 mg/kg were assessed similarly.
The effects of nitroglycerin (2, 4 and 8 mg/kg), phenylephrine (10 mg/
kg) or doxazosin (1 mg/kg) were also assessed as another series of
experiment (n ¼ 6). Our preliminary study conﬁrmed that dox-
azosin at 1 mg/kg decreased the pressor response to phenylephrine
by 85%.
2.3. Drugs
Nicardipine (Perdipine Injection, Astellas Pharma Inc., Tokyo),
nitroglycerin (Millisrol Inj., Nippon Kayaku, Tokyo) and phenyl-
ephrine (Neo-Synesin Inj., Kowa Pharma Co. Ltd, Nagoya) were
purchased and diluted with saline. Doxazosin mesilate was pur-
chased from SigmaeAldrich Japan (Tokyo, Japan) and dissolved in
5% glucose solution. The following drugs were purchased: keta-
mine (Ketalar for intramuscular injection, Daiichi Sankyo, Tokyo),
xylazine (Selacta, Bayer, Osaka), halothane (Fluothane, Takeda
Chemical Industries, Osaka), and heparin sodium (Ajinomoto
Pharmaceuticals, Tokyo, Japan).
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Data are presented as mean ± S.E.M. The statistical signiﬁcances
within a parameter were evaluated by one-way repeated-measures
analysis of variance (ANOVA) followed by Dunnett's test for mean
values comparison using the software Prism 6 (GraphPad Software.
Inc., San Diego, California, USA). A p-value less than 0.05 was
considered signiﬁcant.3. Results
3.1. Effects of nicardipine and nitroglycerin on arterial pulse wave
and CAVI
The typical traces of the effects of nicardipine and nitroglycerin
on the electrocardiogram, phonocardiogram and pulse waveform
obtained from the brachial and tibial arteries are shown in Fig. 2. In
these animals, the height of the dicrotic notch, determined by theFig. 2. The typical traces of the effects of nicardipine at 3 mg/kg (A) and nitroglycerin at 4 mg
the brachial and tibial arteries. Arrows indicate dicrotic notch.difference of blood pressure between end-diastolic nadir and
dicrotic notch, was not affected by nicardipine, whereas it was
reduced by nitroglycerin. Meanwhile, the CAVI decreased only in
the nitroglycerin-treated rabbit.3.2. Effects of nicardipine on hemodynamics, CAVI and haPWV
The time courses of changes in the heart rate, brachial arterial
blood pressure, CAVI, haPWV, femoral arterial blood ﬂow and
femoral vascular resistance by nicardipine administration are
summarized in Fig. 3.
After the low-dose administration of nicardipine (1 mg/kg), no
signiﬁcant change was detected in the heart rate, blood pressure,
CAVI or haPWV. The femoral arterial blood ﬂow increased, whereas
the femoral vascular resistance decreased. After the middle-dose
administration of nicardipine (3 mg/kg), no signiﬁcant change was
detected in the heart rate or CAVI. The systolic and diastolic blood
pressure, haPWV, and femoral vascular resistance decreased,/kg (B) on the electrocardiogram, phonocardiogram and pulse waveform obtained from
Fig. 3. Time courses of the effects of nicardipine on the heart rate, systolic (inverted triangles) and diastolic (triangles) brachial arterial blood pressures, CAVI, haPWV, femoral
arterial blood ﬂow and femoral vascular resistance. The pre-drug control values were 216 ± 11 beats/min, 65 ± 4 mmHg, 49 ± 4 mmHg, 3.4 ± 0.4, 3.4 ± 0.2 m/s, 8.6 ± 2.6 mL/min and
6.2 ± 1.1 mmHg$(mL/min)1, respectively. Nicardipine at 3 and 10 mg/kg decreased the mean blood pressure by 6±1 and 13 ± 3 mmHg, respectively. The high dose increased the
CAVI by þ0.4 ± 0.1. Nicardipine at 1, 3 and 10 mg/kg decreased the femoral vascular resistance to 16 ± 4, e37 ± 6 and 49 ± 9%, respectively. Each value of femoral arterial blood
ﬂow and femoral vascular resistance is expressed as a percentage compared with that at 0 min (¼100%). Data are presented as mean ± S.E.M. (n ¼ 6). The closed symbols represent
signiﬁcant differences from corresponding control value of each parameter by p < 0.05.
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high-dose administration of nicardipine (10 mg/kg), no signiﬁcant
change was detected in the heart rate. The systolic and
diastolic blood pressure, haPWV, and femoral vascular resistance
decreased, whereas the CAVI and femoral arterial blood ﬂow
increased.3.3. Effects of nitroglycerin on hemodynamics, CAVI and haPWV
The time courses of changes in the heart rate, brachial arterial
blood pressure, CAVI, haPWV, femoral arterial blood ﬂow and
femoral vascular resistance by nitroglycerin administration are
summarized in Fig. 4.
Fig. 4. Time courses of the effects of nitroglycerin on the heart rate, systolic (inverted triangles) and diastolic (triangles) brachial arterial blood pressures, CAVI, haPWV, femoral
arterial blood ﬂow and femoral vascular resistance. The pre-drug control values were 209 ± 9 beats/min, 65 ± 3 mmHg, 49 ± 3 mmHg, 3.2 ± 0.2, 3.4 ± 0.1 m/s, 6.7 ± 0.5 mL/min and
6.1 ± 0.4 mmHg$(mL/min)1, respectively. Nitroglycerin at 2, 4, and 8 mg/kg decreased the mean blood pressure by 4±1, e6±1, and 9±2 mmHg and the CAVI by 0.2 ± 0.1,
e0.4 ± 0.1, and 0.4 ± 0.1, respectively. Nitroglycerin at 2, 4 and 8 mg/kg decreased the femoral vascular resistance by 17 ± 1, e19 ± 4 and 25 ± 4%, respectively. Each value of
femoral arterial blood ﬂow and femoral vascular resistance is expressed as a percentage compared with that at 0 min (¼100%). Data are presented as mean ± S.E.M. (n ¼ 6). The
closed symbols represent signiﬁcant differences from corresponding control value of each parameter by p < 0.05.
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systolic and diastolic blood pressure, haPWV, CAVI, and femoral
vascular resistance decreased, whereas the femoral arterial blood
ﬂow increased. After the middle-dose administration of nitroglyc-
erin (4 mg/kg), the systolic and diastolic blood pressure, haPWV,
CAVI, and femoral vascular resistance decreased. After the high-
dose administration of nitroglycerin (8 mg/kg), the systolic and
diastolic blood pressure, haPWV, CAVI, and femoral vascularresistance decreased, whereas the heart rate and femoral arterial
blood ﬂow increased.
3.4. Effects of phenylephrine and doxazosin on hemodynamics, CAVI
and haPWV
The time courses of changes in the heart rate, brachial arterial
blood pressure, CAVI, haPWV, femoral arterial blood ﬂow and
Fig. 5. Time courses of the effects of phenylephrine (A) and doxazosin (B) on the heart rate, systolic (inverted triangles) and diastolic (triangles) brachial arterial blood pressures,
CAVI, haPWV, femoral arterial blood ﬂow and femoral vascular resistance. In phenylephrine group, the pre-drug control values were 228 ± 15 beats/min, 66 ± 4 mmHg,
49 ± 3 mmHg, 3.7 ± 0.3, 3.6 ± 0.1 m/s, 8.1 ± 0.6 mL/min and 6.4 ± 0.6 mmHg$(mL/min)1, respectively. Phenylephrine increased the mean blood pressure and CAVI
by þ13 ± 2 mmHg and þ0.5 ± 0.2, respectively. In doxazosin group, the pre-drug control value were 216 ± 18 beats/min, 68 ± 3 mmHg, 52 ± 3 mmHg, 3.6 ± 0.2, 3.7 ± 0.2 m/s,
7.9 ± 0.6 mL/min and 7.1 ± 0.6 mmHg$(mL/min)1, respectively. Doxazosin decreased the mean blood pressure and CAVI by 5±1 mmHg and 0.1 ± 0.1, respectively. Each value of
femoral arterial blood ﬂow and vascular resistance is expressed as a percentage compared with that at 0 min (¼100%). Data are presented as mean ± S.E.M. (n ¼ 6). The closed
symbols represent signiﬁcant differences from corresponding control value of each parameter by p < 0.05.
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rized in Fig. 5A and B.
After the administration of phenylephrine at the dose of 10 mg/
kg, the systolic and diastolic blood pressure, haPWV, CAVI, and
femoral vascular resistance increased. After the administration of
doxazosin at the dose of 1 mg/kg as a bolus, the systolic and dia-
stolic blood pressure, haPWV, and CAVI decreased. The femoral
vascular resistance tended to decrease, whose change was not
signiﬁcant statistically.
4. Discussion
In this study, we newly set up the measuring system of the CAVI
in rabbits, which could detect a decrease of the CAVI after intra-
venous administration of an a1-adrenoceptor antagonist doxazosin
(Fig. 5B) as well as the previous clinical investigation (13). Using
this system, we investigated the usefulness of the CAVI as an index
for stiffness of large conduit arteries by comparing effects of
nitroglycerin and nicardipine on the CAVI. The doses of nitroglyc-
erin (2e8 mg/kg) and nicardipine (1e10 mg/kg) were comparable to
those in previous clinical and experimental studies (22e30). This is
the ﬁrst report to show that nitroglycerin decreases the CAVI. In
clinic, Ca2þ channel blockers such as nicardipine have been used
widely for patients with cardiovascular diseases, but based on the
present results, both nitroglycerin and doxazosin could be judged
to be superior to nicardipine in terms of reduction of the CAVI.
4.1. Effects of nicardipine on hemodynamic and CAVI
As shown in Fig. 3, nicardipine decreased the blood pressure and
increased the blood ﬂow rate in the femoral artery. Meanwhile, the
femoral vascular resistance decreased, which is in accordance with
a typical pharmacological action of dihydropyridine Ca2þ channel
blockers that reduce resistance of resistive arterioles more prefer-
entially than conducting vessels (18). The heart rate was unaffected
by any doses of nicardipine, whichmay be associated with its direct
inhibitory action on the sinus nodal activity leading to masking
sympathetic reﬂex-induced tachycardia (31). The haPWV was
decreased by nicardipine in a dose-dependent manner, which re-
ﬂects that PWV itself has an attribute essentially depending on
blood pressure. In contrast, the CAVI was unaffected by low and
middle doses of nicardipine, indicating fundamental features of the
CAVI that is independent of blood pressure (2). On the other hand,
the CAVI increased after the administration of the high dose of
nicardipine. In our preliminary study, it is shown that the CAVI
immediately increased during exsanguination or acute heart fail-
ure. Since the present study showed that an a1-adrenoceptor
agonist phenylephrine increased the CAVI (Fig. 5A), adaptive
mechanisms including elevated sympathetic activity may be
involved in the elevation of the CAVI during the high dose admin-
istration of nicardipine.
4.2. Effects of nitroglycerin on hemodynamic and CAVI
Nitroglycerin has been demonstrated to possess unique vascular
actions that dilate systemic venous vessels more potently than
arterial ones, leading to reduction of cardiac output caused by the
decreased venous return (32). Thus, the hypotensive effects of
nitroglycerin, as shown in Fig. 4, may be mostly associated with
such multifaceted pharmacological actions. Furthermore, Fam and
McGrregor have clearly demonstrated that nitroglycerin preferen-
tially dilates large conductive arterial vessels rather than resistant
arterioles in the canine heart (20). In this study, nitroglycerin
decreased the femoral vascular resistance by17 to25% from the
baseline values, and the extents were less than those of effects ofnicardipine by 16 to 49%, which may reﬂect the difference of
pharmacological properties between nitroglycerin and nicardipine
(20).
In this study, intravenous infusion of nitroglycerin signiﬁcantly
decreased the CAVI in contrast to nicardipine, which returned to
the pre-drug control values immediately after stopping the infu-
sion, as shown in Fig. 4, suggesting that changes in the CAVI may be
associated with the effects of nitroglycerin on arterial vascular tone.
In previous studies, nitroglycerin has been shown to reduce aortic
and large-artery stiffness including brachial artery stiffness (30, 33,
34). Moreover, such drugs are known to decrease the height of
dicrotic notch, resulted from reduction of wave reﬂection caused by
dilation of conduit arteries (33e36). The present study also shows
the changes in the pulse waveform obtained from the brachial ar-
tery during the infusion of nitroglycerin, as shown in Fig. 2,
showing the possible phenomena of dilated conduit arteries and
reduced wave reﬂection (30,33e36). Thus, nitroglycerin decreased
the CAVI probably through functionally reduced arterial stiffness
from the origin of aorta to the ankle of the tibial artery in this study
based on the fundamental of the CAVI.4.3. Utility of CAVI for evaluation of arterial function
Since the CAVI was developed as a surrogate marker for arte-
riosclerosis, the index has vaguely been believed to increase year by
year, as clinically investigated (2, 5). Interestingly, we found that
the CAVI could change at least on the minute time scale during the
administration of nitroglycerin in this study. Arterial stiffness
essentially correlates with arterial structural changes, including
collagen accumulation, elastin fragmentation and degeneration,
and thickening of arterial wall (37). In addition to structural
changes, arterial stiffness is affected by vascular smooth muscle
tone, which can be modiﬁed by cell signaling associated with
paracrine mediators or mechanic-stimulation itself. Based on the
current results with nitroglycerin, phenylephrine and doxazosin, it
may be proposed that the arterial stiffness detected by the CAVI
consists of functional factors in addition to structural properties in
conduit and muscular arteries. The PWV has been widely used to
estimate arterial stiffness in clinic. However, it is uncertainwhether
the parameter could really detect arterial stiffness during antihy-
pertensive therapies, since the PWV is dependent on the blood
pressure as shown in this study using nicardipine. Therefore, the
measurement of CAVI in addition to PWV will provide important
information on quantiﬁcation of arterial stiffness in patients.5. Conclusion
The present results suggest that the CAVI could differentiate
pharmacological properties of vasodilators nicardipine and nitro-
glycerin in anesthetized rabbits and that the CAVI partly reﬂects
the contractile function of conduit and muscular arteries that are
sensitive to nitroglycerin. The current study may contain a key
observation to better understand physiological and/or pathophys-
iological roles of conduit andmuscular arteries that can be detected
by the CAVI.Conﬂict of interest
All authors declare no conﬂict of interest.References
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